Items Per Page 102550 Year All2024202320222021202020192018201720162015201420132012201120102009 December 2, 2024 Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer PDF Version November 8, 2024 Delcath Systems Reports Third Quarter 2024 Results and Business Highlights PDF Version November 1, 2024 Delcath Systems to Participate in Upcoming Investor Conferences PDF Version October 25, 2024 Delcath Systems to Host Third Quarter 2024 Earnings Call PDF Version October 17, 2024 Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results PDF Version September 20, 2024 Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version September 16, 2024 Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups PDF Version August 28, 2024 Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference PDF Version August 28, 2024 Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients PDF Version August 27, 2024 Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients PDF Version
December 2, 2024 Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer PDF Version
November 8, 2024 Delcath Systems Reports Third Quarter 2024 Results and Business Highlights PDF Version
October 17, 2024 Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results PDF Version
September 20, 2024 Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PDF Version
September 16, 2024 Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups PDF Version
August 28, 2024 Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference PDF Version
August 28, 2024 Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients PDF Version
August 27, 2024 Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients PDF Version
